Development and validation of the APTNM staging system: Integration of serum biomarkers with TNM classification for enhanced prognostic stratification following hepatectomy for hepatocellular carcinoma
- 2 January 2026
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (2) , 111384
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shanghai Municipality (22ZR1477900)
- National Natural Science Foundation of China (82425049)
- National Natural Science Foundation of China (82372813)
- National Natural Science Foundation of China (82273074)
- Shanghai Rising-Star Program (22QA1411600)
- National Major Science and Technology Projects of China (2024ZD0520506)
- National Major Science and Technology Projects of China (2024ZD0520500)
This publication has 54 references indexed in Scilit:
- Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic HierarchyHepatology, 2020
- Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular CarcinomaJAMA Surgery, 2019
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinomaTumor Biology, 2016
- Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteriaHepatology, 2015
- The role of hepatic resection in the treatment of hepatocellular cancerHepatology, 2015
- Protein Induced by Vitamin K Antagonist‐II (PIVKA‐II) Is a Reliable Prognostic Factor in Small Hepatocellular CarcinomaWorld Journal of Surgery, 2013
- Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosisHepatology, 2012
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Des-?-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinomaCancer, 2001